Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Cuts Novartis’ Glivec Price By 14 Percent - Tip Of The Iceberg  For MNCs In Korea?

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs announced it will cut the price of Swiss-based Novartis' leukemia drug Glivec (imatinib) by 14 percent. The move is the ministry's first reaction to criticism from patient advocacy groups over inflated prices of multinational drug makers' products

You may also be interested in...



Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program

SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program

South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?

SEOUL - The South Korean government currently has no plans to implement compulsory licensing to help rein in costs for Korean patients being treated for fatal diseases, but will reconsider its stance should negotiations with industry break down, Jeon Jae-Hee, the Minister for Health, Welfare and Family Affairs said Feb. 23

South Korea Govt Proposes “Refund System” To Keep MNC Drug Prices Up, Provide Access To Patients

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs is in pursuit of what it calls a "refunding system" under which multinational companies could sell their products at prices they want under the coverage of the local National Health Insurance System

Related Content

UsernamePublicRestriction

Register

SC071870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel